04/21/1995 - "Intra-day coefficient of variation was less than 9.5%, and inter-day coefficient of variation was less than 14.3% for an AG-331 concentration of 44 ng/ml. This method has been used to characterize the pharmacokinetics of AG-331 in cancer patients as part of ongoing Phase I trials."
04/21/1995 - "High-performance liquid chromatographic method for the determination of AG-331, a novel anti-cancer agent, in human serum and urine using solid-phase extraction and photodiode-array detection."
01/01/1999 - "Phase I study of AG 331, a novel thymidylate synthase inhibitor, in patients with refractory solid tumors."
|2.||Hepatocellular Carcinoma (Hepatoma)
01/01/1994 - "Similar results were also obtained in protection experiments with a human hepatoma cell line, HEPG2, although previous results obtained in colon- and breast-cancer cell lines have suggested TS specific effects for AG-331. "
01/01/1994 - "There was no evidence for any intracellular effect of AG-331 on dihydrofolate reductase (DHFR); however, the low degree of cross-resistance found for the H35FF line, which has elevated TS levels, suggested that TS may not be the sole locus of action of AG-331 in hepatoma cells. "
|3.||Breast Neoplasms (Breast Cancer)
|2.||Tetrahydrofolate Dehydrogenase (Dihydrofolate Reductase)